BioMed Research Updates: ARRY, ACCP.OB, MCLN.OB |
 |
 |
| Wednesday, 16 December 2009 19:31 |
|
1.) Array BioPharma (NASDAQ: ARRY) Rodman & Renshaw 12/14/09 Rated Market Outperform / Speculative Risk 12-Month Price Target of $10, Last Price $2.66 2.) Access Pharma (OTC: ACCP.OB) NextWave Research 12/16/09 Rated Spec Buy, $7 Price Target, Last Price $3.20 3.) MedClean Technologies (OTC: MCLN.OB) Goldman Small Cap Research 12/9/09 Rated Spec Buy with Near-Term Price Target $0.14, 2010 Price Target $0.40, Last Price $0.03 Disclosure: Long ACCP.OB BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
Below are four stock research reports published within the past week and available to view or download at the 
about 13 hours ago
FDA panel votes against Xgeva; Nervous GlaxoSmithKline Pulls Cash Out of Eurozone: Below is a look at some of th... http://t.co/h6kQSAz6
about 1 day ago
Illumina’s Board Unanimously Rejects Roche’s Offer; Shire Announces FDA Approval of Vyvanse®: Below is a look at... http://t.co/L3FZivQV
about 1 day ago
Achillion ($ACHN) hammered after BofA rates to "Underperform" citing no M&A speculation. What we said last month: http://t.co/usWk95O6
about 2 days ago
Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 2 days ago
Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 2 days ago
Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 2 days ago
$CVM up 17% and technically looks like it may head higher.
about 3 days ago
$ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr
Free Phone Trade Alerts
